Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2204]

Nivolumab immunotherapy safe, feasible during chemoradiation for advanced head and neck cancer

Nivolumab immunotherapy safe, feasible during chemoradiation for advanced head and neck cancer

Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer

Phase II trial shows activity of durvalumab in recurrent/metastatic head and neck cancer

Light-activated cancer drugs without toxic side effects

Light-activated cancer drugs without toxic side effects

Cancer-killing virus acts by alerting immune system

Cancer-killing virus acts by alerting immune system

Teleconsulting to bring specialised expertise in rare cancers across Europe

Teleconsulting to bring specialised expertise in rare cancers across Europe

ASCO GU 2018: Opening new therapeutic avenues in metastatic prostate cancer

ASCO GU 2018: Opening new therapeutic avenues in metastatic prostate cancer

Last Month in Oncology with Dr. Bishal Gyawali: January 2018

Last Month in Oncology with Dr. Bishal Gyawali: January 2018

ASCO GU 2018: Apalutamide delays prostate cancer metastases by more than two years

ASCO GU 2018: Apalutamide delays prostate cancer metastases by more than two years

ASCO GU 2018: Adding immunotherapy to standard treatment slows growth of advanced kidney cancer, with fewer side effects

ASCO GU 2018: Adding immunotherapy to standard treatment slows growth of advanced kidney cancer, with fewer side...

ASCO GU 2018: Chemotherapy added to hormone therapy for prostate cancer improves quality of life

ASCO GU 2018: Chemotherapy added to hormone therapy for prostate cancer improves quality of life

More from ecancer